TreVita, a U.S.-based medical travel company that connects Americans with vetted care abroad, announced on September 23, 2026, the expansion of its regenerative medicine program in Zona Río, Baja California, Mexico. The program now covers additional therapeutic areas, including healthy aging and rejuvenation, sports and orthopedic injuries, among others. This move reflects TreVita's growing focus on regenerative medicine as a core component of its medical travel platform and responds to rising American interest in new approaches to health, recovery, and longevity.
Central to the expansion is an emphasis on individualized physician evaluation rather than predetermined treatment packages. Physicians assess a client's medical history, current condition, diagnostic information, and treatment goals before determining whether the client may be an appropriate candidate and what approach, if any, should be considered. TreVita also stresses greater transparency around the cellular products clients receive, including cell source, count, viability, testing, and documentation. The company provides end-to-end support that spans physician consultations, medical records and diagnostic review, treatment planning, travel logistics, care coordination, and post-treatment follow-up.
"Regenerative medicine is an increasingly important part of the healthcare conversation, but it is also a category where clients need clarity, transparency and strong medical oversight," said Blake Schroeder, CEO of TreVita. "Our goal is to help clients understand their options, remove barriers, connect them with experienced physicians and create a care experience built around safety, care, integrity and support - and most importantly, increased healthspan. Regenerative medicine is highly individualized, and we believe clients deserve clear information and realistic expectations as they evaluate whether it may be appropriate for them."
The expansion comes as the U.S. regenerative medicine market continues to grow rapidly. According to Grand View Research, the market generated approximately $19.5 billion in 2024 and is projected to reach $49.3 billion by 2030, with a compound annual growth rate of approximately 16.8% from 2025 through 2030. For TreVita, this growth supports a broader long-term investment in regenerative medicine. The company is developing additional clinical and laboratory capabilities in Zona Rio that will give it greater involvement across the client journey, from medical evaluation and treatment coordination to cellular quality oversight and follow-up care.
"Our vision is to increase healthspan for our clients. That is far broader than a company that simply helps someone travel for a procedure," Schroeder added. "We are building a regenerative medicine platform where the physicians, the science, the cellular product and the client experience are connected. As we expand, that level of transparency and accountability will continue to guide what we build."
For readers, the expansion signals a notable shift in medical travel toward more structured, physician-led regenerative care. It highlights the importance of verifying cell source, count, and viability before undergoing any stem cell treatment, and it underscores the value of realistic expectations. TreVita does not represent stem cell therapies as cures and does not guarantee outcomes for any disease, injury, or medical condition. The program is available to qualifying clients through its U.S.-based care team. More information is available at TreVita and via NEWMEDIAWIRE.
